Clinical Trial Update: Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) [Phase 1, Phase 2]

View source ↗

Summary

EVER-RECODE is a Phase 1/Phase 2 trial evaluating everolimus in CDK12-deficient metastatic colorectal cancer, and the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Colorectal Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING